Pages that link to "Item:Q2475724"
From MaRDI portal
The following pages link to Adaptive designs for selecting drug combinations based on efficacy-toxicity response (Q2475724):
Displaying 32 items.
- Sequential design for binary dose-response experiments (Q301360) (← links)
- Optimal designs for contingent response models with application to toxicity-efficacy studies (Q389259) (← links)
- Information in a two-stage adaptive optimal design (Q389442) (← links)
- Adaptive optimal designs for dose-finding studies based on sigmoid \(E_{\max}\) models (Q389444) (← links)
- Adaptive Bayesian compound designs for dose finding studies (Q434557) (← links)
- Two-stage adaptive optimal design with fixed first-stage sample size (Q454769) (← links)
- Robust designs for multivariate logistic regression (Q478485) (← links)
- Barycentric algorithm for computing D-optimal size- and cost-constrained designs of experiments (Q513974) (← links)
- Sequential D-optimal designs for generalized linear mixed models (Q622431) (← links)
- Optimal designs for response functions with a downturn (Q710822) (← links)
- The effects of adaptation on maximum likelihood inference for nonlinear models with normal errors (Q830758) (← links)
- Penalized optimal designs for dose-finding (Q1036729) (← links)
- Experimental designs for drug combination studies (Q1621390) (← links)
- Optimal experimental designs for estimating the drug combination index in toxicology (Q1662053) (← links)
- Adaptive oncology Phase I trial design of drug combinations with drug-drug interaction modeling (Q1782097) (← links)
- Multi-drug combination designs with experiments in silico (Q2073540) (← links)
- Random norming AIDS analysis of non-linear regression models with sequential informative dose selection (Q2301071) (← links)
- Adaptive designs for drug combination informed by longitudinal model for the response (Q2423165) (← links)
- Optimal adaptive designs for acute oral toxicity assessment (Q2492920) (← links)
- Adaptive designs for dose-finding based on efficacy-toxicity response (Q2492921) (← links)
- Incorporating Individual and Collective Ethics into Phase I Cancer Trial Designs (Q3013989) (← links)
- Sequential Methods in Multi-Arm Clinical Trials (Q3068083) (← links)
- Experimental design for multi-drug combination studies using signaling networks (Q3119871) (← links)
- A Latent Contingency Table Approach to Dose Finding for Combinations of Two Agents (Q3183236) (← links)
- A New Dose‐Finding Design for Bivariate Outcomes (Q3433237) (← links)
- Bayesian Dose-Finding in Phase I/II Clinical Trials Using Toxicity and Efficacy Odds Ratios (Q3436524) (← links)
- Utility-Based Optimization of Combination Therapy Using Ordinal Toxicity and Efficacy in Phase I/II Trials (Q3576931) (← links)
- A multi‐source adaptive platform design for testing sequential combinatorial therapeutic strategies (Q4628381) (← links)
- On the Choice of a Prior for Bayesian D-Optimal Designs for the Logistic Regression Model with a Single Predictor (Q5418910) (← links)
- Flexible use of copula‐type model for dose‐finding in drug combination clinical trials (Q6055718) (← links)
- Optimized temporal sampling designs of the Weibull growth curve with extensions to the von Bertalanffy model (Q6615743) (← links)
- Combined criteria for dose optimisation in early phase clinical trials (Q6625215) (← links)
